Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

71.4%

-15.1% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

5(71.4%)

Phase 2

1(14.3%)

Phase 4

1(14.3%)

7Total

N/A(5)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT02021201Phase 4Terminated

The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia

Role: lead

NCT01555814Not ApplicableCompleted

Optimization of Treatment and Management of Schizophrenia in Europe (OPTIMISE): Substudy Site Copenhagen

Role: lead

NCT00206986Not ApplicableCompleted

Will Decreased Noradrenergic Activity Normalize Information Processing in Patients With Schizophrenia?

Role: lead

NCT00206947Phase 2Terminated

The CAMPUS Project: Cholinergic Augmentation of Cognitive Deficits in Schizophrenia

Role: lead

NCT00206999Not ApplicableCompleted

The Effect of Imipramine on Early Information Processing

Role: lead

NCT00207064Not ApplicableCompleted

Neurobiological and Neurocognitive Disturbances in First-episode Schizophrenia

Role: lead

NCT00206960Not ApplicableCompleted

Dopaminergic, Functional, Structural, and Cognitive Disturbances in First-episode Schizophrenia

Role: lead

All 7 trials loaded